PDF下载 ( 1230 KB)
Clinical study of high-intensity focused ultrasound therapy in combination with gemcitabine for unresectable pancreatic carcinoma
-
摘要: 目的探讨高强度聚焦超声(HIFU)联合吉西他滨治疗不可切除胰腺癌的疗效和安全性。方法将48例在我院确诊为不可切除胰腺癌患者随机分为HIFU联合吉西他滨组和单纯吉西他滨化疗组。观察治疗后临床受益率、近期有效率、生存率和不良反应。结果联合治疗组和单纯吉西他滨治疗组相比临床受益率(CBR)(83.3%vs 30.0%,P<0.05)、中位生存期(MST)(10.4个月vs 6.4个月,P<0.05)、6和12个月生存率(73.8%,35.2%vs 52.3%,17.3%,P<0.05)差异均具有统计学意义。而疾病控制率(DCR)(82.1%vs 60.0%,P>0.05)和不良反应率两组差异无统计学意义。结论 HIFU是一种安全,无创,疗效确切地治疗胰腺癌的方法。HIFU联合吉西他滨化疗治疗不可切除胰腺癌不良反应无明显增加,且能有效地提高CBR和DCR,延长生存期。Abstract: Objective To study the effect and security of the combination therapy of high-intensity focused ultrasound (HIFU) with gemcitabine for unresectable pancreatic carcinoma.Methods 48 patients with correct diagnosis of advanced unresectable pancreatic carcinoma were divided into two groups, as the HIFU and gemcitabine combination therapy group and the gemcitabine chemotherapy group.The average survival time, 6-month and 12-month survival rates, clinical benefit rates, disease control rates and side effects were evaluated after treatment.Results Compared with the chemotherapy group, the combination therapy group presented higher CBR (83.3% vs 30.0%, P<0.05) as well as better 6 and 12 month survival (73.8% vs 52.3%, P<0.05;35.2% vs 17.3%, P<0.05) and longer MST (10.04 ms vs 6.4ms) .And there were no differences between the two groups in DCR (82.1% vs 60.0%, P>0.05) and adverse effect.Conclusion HIFU is supposed to be an effective and safe therapy for unresectable pancreatic carcinoma.The combination therapy of HIFU and GEM can increase the CBR and DCR, and prolong the survival time without increasing side effects.
-
Key words:
- pancreatic neoplasms /
- high-intensity focused ultrasound /
- gemcitabine
-
[1]Participants in the Paris workshop.The Paris endoscopic classifi-cation of superficial neoplastic lesions:esophagus, stomach, andcolon[J].Gastrointest Endosc, 2003, 58 (6 Suppl) :S3-43. [2]Li D, Xie K, Wolff R, et al.Pancreatic cancer[J].Lancet, 2004, 363 (9414) :1049-1057. [3]Richter A, Niedergethmann M, Sturm JW, et al.Long-term results of partial pancreaticoduodenectomy for ductaladenocarcinoma of the head:25-years experience[J].World J Surg, 2003, 27 (3) :324. [4]周军, 沈琳.胰腺癌辅助化疗及放化疗进展[J].基层医学论坛, 2007, 11 (10) :924-925. [5]Burris HA, Moore MJ, Andersen J, et al.Improvements insurvival and clinical benefit with gemcitabine as first-linetherapy for patients with advanced pancreas cancer:a ran-domized trial[J].J Clin Oncol, 1997, 15 (6) :2403-2413. [6]刘德忠, 王彬, 闫东, 等.胰腺癌综合治疗现状及其价值[J].介入放射学杂志, 2008, 17 (6) :451-455. [7]曾庆东, 吕丽红, 张秀国, 等.高强度聚焦超声联合健择治疗晚期胰腺癌的临床研究[J].中国肝胆外科杂志, 2006, 12 (11) :749-750. [8]龚继芳, 张晓东, 李洁, 等.吉西他滨为基础的化疗方案治疗进展期胰腺癌的临床研究[J].癌症, 2007, 26 (8) :890-894. [9]王晓, 孙靖中.高强度聚焦超声治疗晚期胰腺癌的初步研究[J].中华普通外科杂志, 2002, 17:627. [10]刘哲峰, 李瑛, 周美齐, 等.高强度聚焦超声治疗无法手术切除胰腺癌的临床研究[J].中华医学杂志, 2005, 85 (12) :796-797. -
本文二维码
计量
- 文章访问数: 3520
- HTML全文浏览量: 13
- PDF下载量: 621
- 被引次数: 0
下载:
